Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
You are not logged in so some information on this page has been withheld. To see more, please log in.